Real-life, cohort, retrospective study of therapeutic oral anticoagulation(vitamin-K antagonists,rivaroxaban, apixaban, edoxaban, dabigatran) in bleeding rates, ischemic stroke, or venous thromboembolism
Latest Information Update: 10 Mar 2021
At a glance
- Drugs Acenocoumarol (Primary) ; Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Phenprocoumon (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
- Indications Acute coronary syndromes; Ischaemic stroke; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Mar 2021 Results published in the American Journal of Medicine
- 10 Nov 2019 New trial record
- 24 Oct 2019 Results published in the American Journal of Medicine